Purpose. This study examined the risk factors for, and molecular mechanisms underlying, the increase in carbapenem minimum inhibitory concentrations (MICs) in clinical isolates of Pseudomonas aeruginosa.
INTRODUCTION
Pseudomonas aeruginosa (P. aeruginosa), an organism that causes severe infections, often acquires resistance to several antimicrobials, or is intrinsically resistant. Carbapenems belong to a class of antimicrobial compounds that are effective against infectious diseases caused by P. aeruginosa. However, carbapenem-resistant P. aeruginosa strains are emerging worldwide; indeed, the rate of resistance in most countries ranges from 10 to 50 % [1] . Multiple mechanisms underlying carbapenem resistance have been reported [1, 2] . One such mechanism is the production of carbapenemases such as KPC and GES, which belong to Ambler class A; IMP, VIM, SPM, GIM, NDM and FIM-type metallo-b-lactamases, which belong to Ambler class B; and OXA variant enzymes, which belong to Ambler class D. Another mechanism involves active the export of antimicrobials out of cells via membrane-associated efflux pumps such as MexABOprM, MexXY-OprM, MexCD-OprJ and MexEF-OprN [2] . Finally, loss of the porin protein OprD, a 46 kDa substratespecific outer-membrane protein that facilitates the diffusion of carbapenems into cells, is also responsible for carbapenem resistance [3, 4] . Among these mechanisms, the loss of OprD appears to be the most common carbapenem-resistance mechanism in P. aeruginosa [5, 6] .
The Clinical and Laboratory Standards Institute (CLSI) guidelines [7] categorize P. aeruginosa requiring an imipenem (IPM) and meropenem (MEM) minimum inhibitory concentration (MIC) !8 µg ml À1 as resistant, whereas the European Committee on Antimicrobial Susceptibility testing (EUCAST) version 5.0 [8] categorizes resistance to these drugs as an MIC >8 µg ml
À1
. However, we often encounter P. aeruginosa strains with a carbapenem MIC of 4 or 8 µg ml À1 in the clinical setting. Some studies have examined the mechanisms underlying resistance to carbapenems in strains defined as resistant (an MIC of IPM and/or MEM >8 µg ml À1 ) [9, 10] . However, few studies have examined the mechanism underlying increases in the MICs of carbapenems, particularly in strains showing intermediate or low-level resistance, and there is a lack of studies examining the mechanism underlying increases in the MICs of carbapenems during the course of treatment. According to data from the Japan Nosocomial Infections Surveillance, 2014, 4.0 and 3.8 % of P. aeruginosa isolates have an IPM MIC of 4 and 8 µg ml À1 , respectively, and 5.5 and 4.9 % of P. aeruginosa isolates have a MEM MIC of 4 and 8 µg ml
, respectively. Although this level of resistance is classed as intermediate or low, it may sometimes hamper antimicrobial treatments based on carbapenems alone. Here, we used clinical isolates of P. aeruginosa with the same genetic backgrounds serially isolated from the same patients to examine the mechanism underlying increases in the MICs of carbapenems in vivo during the course of treatment, focusing on the role of OprD. We also performed multiple logistic regression analysis to identify risk factors associated with the increase in carbapenem MICs.
METHODS
Bacterial isolates and susceptibility testing All P. aeruginosa clinical isolates detected at Nagoya University Hospital from April 2012 through March 2013 were collected. The MICs of 17 antimicrobials (piperacillin, piperacillin-tazobactam, cefoperazone-sulbactam, ceftazidime, cefepime, cefozopran, cefsulodin, IPM, MEM, aztreonam, gentamicin, tobramycin, amikacin, minocycline, fosfomycin, ciprofloxacin and levofloxacin) were tested using the MicroScan WalkAway system (Siemens Healthcare Diagnostics, Inc., West Sacramento, CA, USA) with NegCombo 3.12J in routine clinical practice.
Case stratification and data collection All clinical isolates of P. aeruginosa were obtained by the attending physician when deemed necessary. The isolates were obtained from sputum, urine, bile, blood, abscess and a post-operative drain. The MICs of antimicrobials against the isolates were measured as part of routine clinical care. We found that in some cases, P. aeruginosa isolates serially recovered from the same patient showed increased MICs in a stepwise manner during their clinical course. To analyse this phenomenon, we set inclusion and exclusion criteria for the cases as shown in Fig. 1 . The medical devices included endotracheal tubes, artificial grafts or stents, bile duct tubes, feeding tubes, drainage tubes and urinary tract catheters instituted for more than 1 week. We collected information about the antimicrobials used in the 30 days prior to the day of detection for isolates that showed a !fourfold increase in the MICs of any of the antimicrobials tested, or those used prior to the day on which the last isolate was detected if the isolate showed a <fourfold increase in the MICs during the clinical course. Infection with P. aeruginosa isolates was determined retrospectively by two independent infectious disease physicians. The categorical variables were examined using Pearson's chi-square test, and those with a P value <0.1 were entered into multiple logistic regression analysis. Significance was set at P<0.05. The Hosmer-Lemeshow test was used to assess goodness of fit for model calibration. Statistical analysis was performed using SPSS software, version 22 (IBM Japan, Tokyo, Japan).
Pulsed-field gel electrophoresis (PFGE) analysis and selection of isolates Genomic DNA was prepared according to the highly standardized pulsed-field gel electrophoresis (PFGE) protocols of the USA Centers for Disease Control and Prevention (CDC), with some minor modifications [11] . PFGE was performed using a CHEF-DR III pulsed field electrophoresis system (Bio-Rad Laboratories, Hercules, CA, USA), according to the manufacturer's instructions, with some modifications. Briefly, agarose plugs containing genomic DNA were digested with SpeI (TaKaRa Bio, Shiga, Japan). DNA fragments were then separated in a SeaKem Gold agarose gel (Lonza, Rockland, ME, USA) in 0.5 TBE buffer. The run time was 19.7 h at 6.0 V cm À1 at an included angle of 120 , with a switch time ramped from 5.3 to 34.9 s at 14 C. The DNA profiles were analysed using BioNumerics version 7.1 analysis software (Applied Maths NV, Sint-Martens-Latem, Belgium). Isolates were deemed to be derived from the same origin if the Dice coefficient was more than 85 % according to the differentiation criteria (Fig. 2) [12] . We selected a pair of genetically related isolates from each case in group A: one isolate (isolate X) was obtained early in the clinical course and the other (isolate Y) was obtained after the !fourfold increase in the MIC of carbapenems. The two were then compared as described below.
Detection of carbapenemase production via phenotypic tests
The production of carbapenemases was examined using the Carba NP test and the modified carbapenem inactivation method (mCIM) as previously described [13] [14] [15] . The Carba NP test is based on the biochemical reaction of the hydrolysis of the b-lactam ring of a carbapenem as detected by the colour change of a pH indicator [13] .
Molecular identification of carbapenemases via multiplex PCR
Total genomic DNA was extracted using the Cica Geneus DNA extraction reagent (Kanto Chemical Co., Ltd, Tokyo, Japan). Multiplex PCR for carbapenemase genes was performed using five pairs of primers as previously described [16] . The primers are shown in Table 1 . One microlitre of total DNA was subjected to multiplex PCR in a 20 µl reaction mixture, which contained 4 pmol/l of each primer and 10 µl of PrimeSTAR HS (Premix) (TaKaRa Bio). Amplification was carried out with the following conditions: 30 cycles consisting of 10 s at 98 C, 5 s at 55 C and 60 s at 72 C.
Western blot analysis
Western blot analysis was performed as previously described [17] , with some modifications. Briefly, cells were grown in Mueller-Hinton broth (Becton Dickinson and Company, Sparks, MD, USA) and harvested by centrifugation at 3450 g for 20 min at 4 C. The cells were resuspended in 0.05 M PBS (pH 7.0) and then lysed by sonication. After further centrifugation at 1100 g for 10 min to remove unbroken cells, the membranes were pelleted by centrifugation at 23 500 g for 20 min. Proteins (10 µg/lane) were separated on SDS-PAGE gels and transferred to a PVDF membrane. Rather than measuring a housekeeping protein, TGX stain-free precast gels (BioRad Laboratories) were used to measure the expression levels of protein in each lane, as previously described [18] . An anti-OprD antibody [17] , kindly provided by Drs Takashi Ida and Naomasa Gotoh, was used as the primary antibody, and a horseradish peroxidase-linked anti-rabbit IgG antibody (GE Healthcare, Buckinghamshire, UK) was used as the secondary antibody. Bound antibodies were detected using an enhanced chemiluminescent substrate (Thermo Scientific, Rockford, IL, USA). The OprD signal was detected with ImageQuant LAS 4010 (GE Healthcare). Each experiment was performed in triplicate. P. aeruginosa PAO1 strain (PAO1) was used as the reference strain for each experiment. The significance of the differences in the expression of OprD protein was analysed using Welch's t-test.
oprD sequence analysis A region encapsulating the promoter and downstream regions of the oprD gene was amplified by PCR using the primers OprD_FlankF and OprD_FlankR (Table 1) , as previously described [19] . The reaction mixture contained 2 mM MgCl 2 , 0.2 mM of each deoxyribonucleoside triphosphate, 1 µM of each primer and 1.25 units of Ex Taq (TaKaRa Bio) in a total volume of 50 µl. PCR amplification was performed as follows: 95 C for 5 min, followed by 30 cycles of 95 C for 30 s, 55 C for 30 s and 72 C for 2 min. The amplified products were purified using a QIAquick PCR purification kit (Qiagen, Hilden, Germany) and subjected to sequence analysis with additional primer sets (Table 1) , as previously described [19, 20] . DNA sequencing was performed on a 3730xl DNA sequencing instrument (Applied Biosystems, Foster City, Japan) at Riken Gensis Co., Ltd, and sequence analysis was performed using Sequencher 4.10.1 software (Gene Codes Corporation, Ann Arbor, MI, USA). The insertion sequences were characterized using the online tool, ISfinder (https://wwwis.biotoul.fr/). DNA sequences of the oprD genes of P. aeruginosa isolates in this study have been deposited at DDBJ/ EMBL/GenBank databases under the accession numbers LC321995-LC322008. C. RNAprotect bacteria reagent (Qiagen) was used to stabilize the RNA, according to the manufacturer's instructions. Total RNA was purified using an RNeasy mini kit (Qiagen). DNA was removed by treatment with DNase (Qiagen). The quality of the RNA was confirmed by measuring the A 260 /A 280 ratio, and the RNA integrity number was calculated using an Agilent 2100 Bioanalyzer system (Agilent Technologies, Santa Clara, CA, USA) according to MIQE guidelines [21] . The purified RNA was converted to cDNA using a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). The resulting cDNA was then subjected to qPCR using Brilliant III SYBR Green Q-PCR Master mix (Agilent Technologies, Cedar Creek, TX, USA), Mx3000/3005P qPCR systems (Agilent Technologies) and specific primers (Table 1) , as described previously [22, 23] . The PCR conditions were as follows: denaturation for 10 min at 95 C, followed by 40 cycles of 30 s at 95 C and 60 s at 60 C [24] . The rpsL gene was used as a reference for normalization. The levels of mRNA were expressed relative to those in the PAO1. The experiment was performed in triplicate.
RESULTS

Cases and isolates included in the study
From the 266 cases enrolled during the study period, 719 P. aeruginosa isolates were identified: 139 cases with only 1 isolate and 21 cases with multiple isolates collected on the same day were excluded from the study. One hundred and six cases and 532 P. aeruginosa isolates were included in the analysis. Of these 106 cases, 64 harboured P. aeruginosa isolates showing a !fourfold increase in the MIC of any antimicrobial tested. Of the 64 cases, 27 (group A) harboured 238 P. aeruginosa isolates showing a !fourfold increase in Clonal relationships based on PFGE analysis PFGE analysis was used to examine the clonal relationship between paired P. aeruginosa isolates from the patients in group A before and after the !fourfold increase in the MICs of carbapenems. Paired P. aeruginosa isolates (isolate X and isolate Y) from 19 cases showed high homology in the Dice clustering dendrogram during PFGE analysis; therefore, they were considered to have the same genetic origin (Fig. 2) . Table 3 shows the relative expression levels of OprD protein after the !fourfold increase in the MIC in ascending order. According to Table 3 , the 19 paired isolates could be divided into 2 subgroups: 1 included 12 paired isolates for which the MIC of IPM was more than 8 µg ml À1 (subgroup A1, cases 1-12) after the !fourfold increase and the other included 7 for which the MIC of IPM was 4 or 8 µg ml
À1
(subgroup A2, cases [13] [14] [15] [16] [17] [18] [19] after the !4-fold increase. The mean expression level of OprD protein by isolates in subgroup A1 after the increase in the MIC of IPM was 0.023, while that of the isolates in subgroup A2 was 0.37, which was significantly higher (P=0.002). Fig. 3(a) shows that OprD protein expression by the isolates in subgroup A1 fell to very low (almost undetectable) levels after the increase in the MIC of IPM. By comparison, Fig. 3(b) shows that most of the isolates in subgroup A2 showed a quantitative decrease in OprD protein expression after the increase in the MIC of IPM, but not to the levels seen in subgroup A1. There was no close relationship between increased MICs for MEM and decreased OprD protein expression.
Mutation of the oprD gene
The oprD gene was sequenced, including the promoter and downstream regions. The genetic alterations in oprD identified in isolates before and after the !fourfold increase in the MIC are shown in Table 4 . Of the 12 isolates in subgroup A1, 11 showed some alterations in the oprD gene after the increase in the MIC of IPM ( Table 3 ). As shown in Table 4 , 5/11 isolates harboured deletions and 2 harboured a single base substitution (G to A); one of these 2 also harboured a 12 bp deletion. Three isolates harboured a one-base insertion. The other two isolates harboured a multiple base insertion: a 347 bp repeat insertion and a 1212 bp insertion that shared 99 % similarity with ISPa9 of P. aeruginosa. All these genetic changes led to frameshifts or introduced an immature termination codon, which led to the loss of functional OprD protein. All seven paired isolates belonging to subgroup A2 and one paired isolate belonging to subgroup A1 showed no changes in the nucleotide sequence of the oprD gene or surrounding regions.
Expression of oprD mRNA Expression of oprD mRNA was measured by qPCR. Table 3 shows that, out of seven paired isolates in subgroup A2, six showed reduced expression of oprD mRNA after the increase in the MICs of IPM, while one (isolate 18) showed increased oprD mRNA expression. One isolate in subgroup A1, which harboured no mutation after the increase in the MIC of IPM, showed significantly reduced expression of oprD mRNA. These results support the reduction of OprD protein expression detected by Western blotting.
The mRNA expression of Mex efflux pumps was measured by qPCR (data not shown). Two isolates (isolates 12 and 18) showed upregulated mRNA expression of mexR, mexA and oprM, and the MICs of MEM were higher in these isolates than in the other isolates. There was no correlation between upregulation of the mexT, mexE and oprN genes and susceptibility to IPM or MEM.
DISCUSSION
Here, we examined the mechanism underlying the increases in the MICs of carbapenems for paired genetically related P. aeruginosa isolates recovered from the same patient during the course of treatment, focusing on the role of OprD. Although previous studies reported reduced expression of oprD mRNA by qPCR [25, 26] and reduced expression of OprD protein by Western blot analysis [27] , not enough studies have examined the increased carbapenem MICs observed in P. aeruginosa isolates serially recovered from the same patients during daily clinical practice. Moreover, as far as we are aware, the present study is the first to accurately quantify OprD protein expression in P. aeruginosa by Western blot analysis using TGX stain-free precast gels (Bio-Rad Laboratories), which allow more accurate quantification of protein than conventional polyacrylamide gels [18] . The results revealed that P. aeruginosa isolates tended to lose the expression of OprD protein at higher IPM MICs (>8 µg ml À1 ), whereas a reduction in OprD protein expression occurred at lower MICs (4 or 8 µg ml À1 ). These data were supported by qPCR analysis of oprD mRNA expression. Moreover, sequence analysis of the oprD gene, including the promoter and downstream regions, revealed that most of the isolates with an IPM MIC >8 µg ml À1 harboured deletions, mutations, or insertions in the oprD gene, which led to a frameshift or the introduction of translational stop codons in the oprD gene and the loss of functional OprD protein (as previously reported by Ocampo-Sosa et al. [19] ). From the previous reports, there were three patterns of mutations in the oprD gene [28, 29] . One was point mutation, leading to premature termination codons. The second was frameshift mutation by insertion or deletion of one or more nucleotides, which can also lead to termination codons. The last was disruption by insertion sequences. Although the mutation sites were highly diverse, in our results the patterns of the mutations in the oprD gene were similar to those of previous reports [23, [28] [29] [30] . The 347-bp repeat insertion that was seen in strain 11Y has not been reported previously. It might be a novel repeat insertion sequence, but the precise structures and functions were not clarified in this study. Further investigation is needed.
On the other hand, P. aeruginosa isolates with an IPM MIC of 4 or 8 µg ml À1 (subgroup A2) harboured no mutations in the oprD gene, including the promotor region. Therefore, another mechanism must play a role in these lower increases in the IPM MIC. One possible mechanism is transcriptional or post-transcriptional regulation by MexT. The mexT gene, which is located upstream of the mexEF-oprN operon, positively regulates transcription of the mexEFoprN genes and, at the same time, negatively regulates oprD at the transcriptional and post-transcriptional levels, leading to reduced production of OprD protein [31, 32] . From our results, we could not find a correlation between reduced oprD expression and upregulation of mexT, mexE, or oprN. Further research is needed using larger numbers of isolates. Of the seven isolates in subgroup A2, only one showed increased protein and mRNA expression of OprD after the increase in the IPM MIC. The mechanism underlying the discordance between OprD expression and the increase in the IPM MIC should be clarified in a future study.
A close correlation between the increase in MIC and the loss or reduction of OprD protein expression was observed for IPM, but not MEM. Therefore, resistance to IPM and MEM may occur via distinct mechanisms [33, 34] . Upregulation of MexAB-OprM may induce resistance to MEM, which, unlike IPM, is a substrate for MexAB-OprM [35] [36] [37] . Two isolates (isolates 12 and 18) showed upregulation of mexR, mexA and oprM mRNA, and the MEM MIC was higher in these isolates than in the other isolates. In these strains, the increased MEM MICs are assumed to be caused by the hyperproduction of an efflux system of MexABOprM [6, 38, 39] The aim of our study was to analyse the increased MICs of carbapenems in P. aeruginosa clinical isolates that we encountered frequently in daily practice. Therefore, we used the MICs of antimicrobials determined using the MicroScan WalkAway system to reflect the daily clinical situation for the determination of drug susceptibility, although discrepancies have been reported between MICs determined using commercial systems such as the MicroScan WalkAway system and those determined using reference methods such as the broth microdilution, agar dilution and disk diffusion methods [40, 41] . The clinical breakpoints of IPM determined by the CLSI and EUCAST are discordant, with an MIC !8 µg ml À1 indicating resistance in the former, and an MIC >8 µg ml À1 indicating resistance in the latter. The present study revealed a difference in resistance mechanisms between isolates with MICs % 8 µg ml À1 and those with MICs >8 µg ml
À1
, which might support the latter criterion.
Our findings may have clinical implications. Lister et al. [42] showed that combination therapy using IPM with levofloxacin was effective against infectious diseases caused by P. aeruginosa, but this depended on the MIC of IPM. They found that combination therapy is effective when the levofloxacin and IPM MICs against the causative P. aeruginosa are 4 and 8 µg ml
, respectively. However, combination therapy is not effective against strains for which the levofloxacin and IPM MICs are 4 and 32 µg ml À1 , respectively. From the viewpoint of the present study, the former P. aeruginosa (MIC of IPM=8 µg ml
) isolates only had their OprD expression reduced, and combination therapy might still be effective; however, the latter isolates (MIC of IPM=32 µg ml
) had no functional OprD expression, and the effect of combination therapy might be lost.
Multiple logistic regression analysis identified the prior use of carbapenems and the use of a ventilator or tracheostomy as risk factors for a !fourfold increase in the MICs of carbapenems. These same risk factors have been identified in previous reports [43] [44] [45] of carbapenem-resistant P. aeruginosa. These major risk factors even affect the development of intermediate or low-level resistance to carbapenems in P. aeruginosa clinical isolates.
This study reports that loss of functional OprD protein occurs with high IPM MICs (>8 µg ml À1 ), whereas OprD protein expression is reduced with lower MICs (4 or 8 µg ml À1 ) in P. aeruginosa isolates serially recovered from the same patients during the clinical course. Therefore, an IPM MIC of 8 µg ml À1 would be the critical breakpoint in the treatment of infectious diseases caused by IPM-resistant P. aeruginosa. Judicious use of antimicrobials and reduced usage of carbapenems may prevent P. aeruginosa from acquiring resistance to IPM.
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